Insmed (INSM) reported $606M in revenue for fiscal 2025, +66.7% year on year. That ranks #2099 by revenue among 2853 SEC filers and #201 in Healthcare. It posted a net loss of −$1.3B for the same year. Revenue has grown 42.1% a year on average since 2011 ($4.4M then). The fiscal 2025 balance sheet shows $2.3B in total assets, $510M in cash and $541M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $606M | +66.7% | FY20252025-12-31 |
| Gross profitGrossProfit | $112M | +1,414.5% | FY20192019-12-31 |
| Operating incomeOperatingIncomeLoss | −$1.2B | −$369M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$1.3B | −$363M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$935M | −$251M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $32.6M | +48.5% | FY20252025-12-31 |
| Total assetsAssets | $2.3B | +11.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $739M | +158.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $510M | −8.0% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $541M | −51.0% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $306M | −$164M | Open → |
| Q2 20262026-06-30 | $425M | −$13.2M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Insmed Inc
- Ticker
- INSM
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001104506
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 19, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| TG TherapeuticsTGTX | $616M | $447M |
| Cadre HoldingsCDRE | $610M | $44.1M |
| Opko HealthOPK | $607M | −$226M |
| InsmedINSM | $606M | −$1.3B |
| Transmedics GroupTMDX | $605M | $190M |
| Ufp TechnologiesUFPT | $603M | $68.3M |
| Catalyst PharmaceuticalsCPRX | $589M | $214M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Insmed — Key figures |url=https://companiesranked.com/en/company/insmed |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Insmed — Key figures. CompaniesRanked. https://companiesranked.com/en/company/insmedBibTeX
@misc{companiesranked-en-company-insmed-2026,
author = {{CompaniesRanked}},
title = {{Insmed — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/insmed}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001104506-26-000009 · February 19, 2026
{{cite web |title=Insmed — Key figures — 10-K (0001104506-26-000009) |url=https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/insm-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-19}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.